Poolbeg PharmaPOLBF Receivables Turnover is 0.00 as of Dec. 2025. The stock has 1 warning sign investors should review. Among 841 Biotechnology companies, Poolbeg Pharma ranks worse than 118905.95% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Poolbeg Pharma's Revenue for the
six
months ended in Dec. 2025 was $0.00 Mil. Poolbeg Pharma's average Accounts Receivable for the
six
months ended in Dec. 2025 was $0.05 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Poolbeg Pharma Receivables Turnover Related Terms
Poolbeg Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Poolbeg Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
POLBF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Poolbeg Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poolbeg Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Poolbeg Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poolbeg Pharma (POLBF) has a Receivables Turnover of 0.00 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Poolbeg Pharma and its competitors. According to the industry distribution chart, Poolbeg Pharma ranks #999999 out of 841 companies in the Biotechnology industry.
Is Poolbeg Pharma's Receivables Turnover too high?
Poolbeg Pharma's current Receivables Turnover is 0.00. Based on the distribution chart, Poolbeg Pharma ranks #999999 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Poolbeg Pharma's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #999999 out of 841 companies for Receivables Turnover. This places Poolbeg Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Poolbeg Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poolbeg Pharma's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POLBF has been successfully added to your 